Pde3a - phosphodiesterase 3A Gene

Also Known as RNPDE3A

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 50678

About Pde3a

Primary_assembly 4: 174,172,868-174,438,274 forward strand.mRatBN7.2:CM026977.1

This gene has 1 transcript (splice variant), 258 orthologues, 20 paralogues and is associated with 10 phenotypes. Biased expression in Heart (RPKM 245.3), Lung (RPKM 86.5) and 8 other tissues.

Summary

Predicted to enable 3',5'-cyclic-AMP phosphodiesterase activity. Involved in negative regulation of apoptotic process; negative regulation of cAMP-mediated signaling; and oocyte maturation. Located in cytosol. Biomarker of obesity and pulmonary hypertension. Human ortholog(s) of this gene implicated in hypertension and brachydactyly syndrome. Orthologous to human PDE3A (phosphodiesterase 3A). [provided by Alliance of Genome Resources, Apr 2022]

Pde3a Products (1)

mRNA Protein Name
NM_017337.1 NP_059033.1 cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence References Source
involved in negative regulation of apoptotic process IMP
IMP: Inferred from mutant phenotype
15867171 RGD
involved in negative regulation of cAMP/PKA signal transduction IMP
IMP: Inferred from mutant phenotype
9884079 RGD
involved in oocyte maturation IEP
IEP: Inferred from expression pattern
11673261 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Pde3a Protein Structure

PDEase_I

PDEase_I: pfam00233 (750 - 1011)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000
  • 1141 a.a.
Protein Preferred Names Protein Names

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A

cGMP-inhibited 3',5'-cyclic phosphodiesterase A

  • CGI-PDE A

  • cyclic GMP-inhibited phosphodiesterase A

  • cyclic nucleotide phosphodiesterase

  • phosphodiesterase 3A, cGMP inhibited

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Phase
HY-112831 Osoresnontrine Inhibitor 99.94% Phase 2
HY-A0165 Tofisopam Inhibitor 99.94% Phase 2
HY-U00186 K134 Inhibitor 99.76% Phase 2
HY-111167 AN-2898 Inhibitor / Phase 2
HY-145924 BAY 2666605 Inhibitor 99.74% Phase 1

Pre-clinical Phase

Bioactive Molecules (23)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-101312 Cilostamide Inhibitor 99.13% Unkown
HY-136350 BRD9500 Modulator 98.41% Unkown
HY-W028690 DNMDP Inhibitor 99.46% Unkown
HY-162730 OPB-171775 Inhibitor 99.80% Unkown
HY-100530C Sp-cAMPS sodium salt 99.45% Unkown
HY-122751 (R)-DNMDP Inhibitor 99.59% Unkown
HY-100530B Sp-cAMPS / Unkown
HY-136350B (S)-BRD9500 Control 99.67% Unkown
HY-N10149 Nauclefine 99.65% Unkown
HY-110005 Sp-cAMPS triethylamine / Unkown
HY-112631 OPC 33540 Inhibitor / Unkown
HY-120945 PDE10A-IN-1 Inhibitor / Unkown
HY-153802 Antitumor agent-100 Inducer / Unkown
HY-153802A Antitumor agent-100 hydrochloride Inducer / Unkown
HY-174383 PDE3/4-IN-2 Inhibitor 99.75% Unkown
HY-176524S PDE3/4-IN-3 Inhibitor / Unkown
HY-179503 PDE/TRPA1/CHIT1-IN-1 Inhibitor / Unkown
HY-181088 PDE3/4-IN-4 Inhibitor / Unkown
HY-181762 Multitarget AD-IN-6 Inhibitor / Unkown
HY-RS10216 PDE3A Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS10217 Pde3a Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS10218 Pde3a Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-162730R OPB-171775 (Standard) Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Pde3a NCBI NCBI:5139